Meeting
2017 ASCO Annual Meeting
Effect of treating glioblastoma with a cytokine inhibitor, ibudilast, in combination with temozolomide on survival in a patient-derived xenograft model.
Authors
Kerrie Leanne McDonald
University of NSW, Kensington, Australia
Kerrie Leanne McDonald , Wendy Ha , Hatice Sevim , Kazuko Matsuda , Mustafa Khasraw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2062)
DOI
10.1200/JCO.2017.35.15_suppl.2062
Abstract #
2062
Poster Bd #
304
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2022 ASCO Annual Meeting
Clinical application of a functional 3D ex vivo test to predict therapeutic response in patients with HGG: A progression-free survival analysis.
First Author: Lindsay J Lipinski
Poster
2023 ASCO Annual Meeting
A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.
First Author: Paul James Mulholland
Poster
2022 ASCO Annual Meeting
Design and initiation of an adaptive, randomized, controlled study of berubicin, a topoisomerase 2 poison that crosses the blood brain barrier (BBB), for the treatment of recurrent glioblastoma multiforme (GBM) after first-line therapy.
First Author: Sandra Silberman